1. See Peter Drahos and John Braithwaite, *Information Feudalism* (New York: New Press, 2003), Chapter 4.
2. *United States – Section 337 of the Tariff Act of 1930* L 6439 (1989).
3. Drahos and Braithwaite, supra note 1. See also A. Taubman, H. Wager and J. Watal, *A Handbook on the WTO TRIPS Agreement* (Cambridge: Cambridge University Press 2012).
4. Panel Report, *Australia – Certain Measures concerning Trademarks, Geographical Indications and other Plain Packaging Requirements applicable to Tobacco Products and Packaging*, WT/ DS435, 441, 458, 467/R, para. 7.2430, circulated to WTO Members 28 June 2018 [appealed by the Dominican Republic and Honduras]. See also B. Hawkins, C. Holden and S. Mackinder, “A Multi- level, Multi-Jurisdictional Strategy: Transnational Tobacco Companies’ Attempts to Obstruct Tobacco Packaging Restrictions”, (2019) 14(4) *Global Public Health* 570.
5. See Tomer Broude, “Taking ‘Trade and Culture’ Seriously: Geographical Indications and Cultural Protection in WTO Law”, (2004) 26(4) University of Pennsylvania Journal of International Economic Law 623–92.
6. See Drahos and Braithwaite, supra note 1.
7. *EU – Canada Patent Protection of Pharmaceuticals* (2000) WT/DS114/R.
8. See Alan O. Sykes, “TRIPS, Pharmaceuticals, Developing Countries and the Doha Solution”, (2002) 3(1) *Chicago Journal of International Law* 47.
9. See, for example, Institute for Health Metrics and Evaluation, *Financing Global Health 2013: Transition in an Age of Austerity* (Seattle: Institute for Health Metrics and Evaluation). Online: http:// [www.healthdata.org/sites/default/files/files/policy\_report/2014/FGH2013/IHME\_](http://www.healthdata.org/sites/default/files/files/policy_report/2014/FGH2013/IHME_) FGH2013\_Full\_ Report.pdf. Accessed 14 July 2014; Faiz Kermani, “Maintaining the Focus for Neglected Diseases: Product Development Partnerships Seek to Bridge the Healthcare Gap”, Contract Pharma (2011). Online: [http://www.contractpharma.com/issues/2011–10/view\_features/maintaining-the-focus-](http://www.contractpharma.com/issues/2011) for-neglected-diseases/. Accessed 14 July 2014; Stephen M. Maurer, “Choosing the Right Incentive Strategy for Research and Development in Neglected Diseases”, (2006) *Bulletin of the World Health Organization*. Online: [http://www.who.int/bul-letin/volumes/84/5/376.pdf. Accessed 14 July 2014](http://www.who.int/bul-letin/volumes/84/5/376.pdf.%20Accessed%2014%20July%202014); M. Moran, G. Guzman, A.L. Ropars and A. Illmer, “The Role of Product Development Partnerships in Research and Development for Neglected Diseases”, (2010) 2(2) *International Health* 114–22.
10. See, for example, Institute for Health Metrics and Evaluation, *Financing Global Health 2013: Transition in an Age of Austerity* (Seattle: Institute for Health Metrics and Evaluation). Online: http:// [www.healthdata.org/sites/default/files/files/policy\_report/2014/FGH2013/IHME\_](http://www.healthdata.org/sites/default/files/files/policy_report/2014/FGH2013/IHME_) FGH2013\_Full\_ Report.pdf. Accessed 14 July 2014; Faiz Kermani, “Maintaining the Focus for Neglected Diseases: Product Development Partnerships Seek to Bridge the Healthcare Gap”, Contract Pharma (2011). Online: [http://www.contractpharma.com/issues/2011–10/view\_features/maintaining-the-focus-](http://www.contractpharma.com/issues/2011) for-neglected-diseases/. Accessed 14 July 2014; Stephen M. Maurer, “Choosing the Right Incentive Strategy for Research and Development in Neglected Diseases”, (2006) *Bulletin of the World Health Organization*. Online: [http://www.who.int/bul-letin/volumes/84/5/376.pdf.](http://www.who.int/bul-letin/volumes/84/5/376.pdf) Accessed 14 July 2014; M. Moran, G. Guzman, A.L. Ropars and A. Illmer, “The Role of Product Development Partnerships in Research and Development for Neglected Diseases”, (2010) 2(2) *International Health* 114–22.
11. See Deborah Gleeson, Joel Lexchin, and Ruth Lopert, “The Trans-Pacific Partnership Agreement, Intellectual Property and Medicines: Differential Outcomes for Developed and Developing Countries”, (2018) 18(1) *Global Social Policy* 7–27.